blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3568142

EP3568142 - THERAPEUTIC PEPTIDES THAT TARGET TGF-BETA INTERACTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.01.2023
Database last updated on 28.03.2026
FormerThe patent has been granted
Status updated on  11.02.2022
FormerGrant of patent is intended
Status updated on  28.11.2021
FormerRequest for examination was made
Status updated on  28.07.2021
FormerGrant of patent is intended
Status updated on  03.05.2021
FormerRequest for examination was made
Status updated on  30.03.2021
FormerGrant of patent is intended
Status updated on  18.11.2020
FormerRequest for examination was made
Status updated on  18.10.2019
FormerThe international publication has been made
Status updated on  20.07.2018
Formerunknown
Status updated on  12.02.2018
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Genagon Therapeutics AB
Nanna Svartz Väg 2
171 65 Solna / SE
[2019/47]
Inventor(s)01 / BLOKZIJL, Olof Andries
11338 Stockholm / SE
02 / FREDRIKSSON, Johan Erik Simon
Kiviksvägen 2
16854 Bromma / SE
 [2022/10]
Former [2019/47]01 / BLOKZIJL, Olof Andries
Upplandsgatan 69
11328 Stockholm / SE
02 / FREDRIKSSON, Johan Erik Simon
Kiviksvägen 2
16854 Bromma / SE
Representative(s)Dehns
10 Old Bailey
London EC4M 7NG / GB
[N/P]
Former [2019/47]Dehns
St. Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
Application number, filing date18702417.912.01.2018
[2019/47]
WO2018EP50776
Priority number, dateGB2017000056712.01.2017         Original published format: GB 201700567
[2019/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018130659
Date:19.07.2018
Language:EN
[2018/29]
Type: A1 Application with search report 
No.:EP3568142
Date:20.11.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 19.07.2018 takes the place of the publication of the European patent application.
[2019/47]
Type: B1 Patent specification 
No.:EP3568142
Date:16.03.2022
Language:EN
[2022/11]
Search report(s)International search report - published on:EP19.07.2018
ClassificationIPC:A61K35/17, A61K38/00, G01N33/68, A61P35/00, A61K31/00, C07K14/71, A61K39/00, C07K14/495
[2020/50]
CPC:
A61P35/00 (EP); A61K35/17 (EP,US); C07K14/495 (EP,US);
C07K14/71 (EP,US); A61K38/00 (EP,US); C07K2317/54 (US);
C07K2317/55 (US); C07K2317/56 (US); C07K2319/00 (EP) (-)
Former IPC [2019/47]A61K35/17, A61K39/00, C12N5/0783, C07K14/71, A61K31/00, A61P35/00, G01N33/68, A61K38/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/47]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:THERAPEUTISCHE PEPTIDE MIT ABZIELUNG AUF TGF-BETA-INTERAKTION[2019/47]
English:THERAPEUTIC PEPTIDES THAT TARGET TGF-BETA INTERACTION[2019/47]
French:PEPTIDES THÉRAPEUTIQUES CIBLANT L'INTERACTION TGF-BÊTA[2019/47]
Entry into regional phase01.07.2019National basic fee paid 
01.07.2019Designation fee(s) paid 
01.07.2019Examination fee paid 
Examination procedure01.07.2019Examination requested  [2019/47]
01.07.2019Date on which the examining division has become responsible
20.02.2020Amendment by applicant (claims and/or description)
19.11.2020Communication of intention to grant the patent
29.03.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.05.2021Communication of intention to grant the patent
27.07.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
29.11.2021Communication of intention to grant the patent
02.02.2022Fee for grant paid
02.02.2022Fee for publishing/printing paid
02.02.2022Receipt of the translation of the claim(s)
Opposition(s)19.12.2022No opposition filed within time limit [2023/08]
Fees paidRenewal fee
20.01.2020Renewal fee patent year 03
20.01.2021Renewal fee patent year 04
18.01.2022Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY12.01.2018
HU12.01.2018
AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
IT16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
TR16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
[2026/04]
Former [2025/39]CY12.01.2018
HU12.01.2018
AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
IT16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2025/36]CY12.01.2018
AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
IT16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2024/29]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
IT16.03.2022
LT16.03.2022
LV16.03.2022
MC16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2023/35]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
IT16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2023/10]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SI16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2023/07]AL16.03.2022
AT16.03.2022
CZ16.03.2022
DK16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2023/01]AL16.03.2022
AT16.03.2022
CZ16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2022/51]AT16.03.2022
CZ16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
IS16.07.2022
PT18.07.2022
Former [2022/50]AT16.03.2022
CZ16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
PL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
PT18.07.2022
Former [2022/49]AT16.03.2022
CZ16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SK16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
PT18.07.2022
Former [2022/48]AT16.03.2022
CZ16.03.2022
EE16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
PT18.07.2022
Former [2022/47]AT16.03.2022
ES16.03.2022
FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
RO16.03.2022
RS16.03.2022
SE16.03.2022
SM16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
PT18.07.2022
Former [2022/44]FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
NL16.03.2022
RS16.03.2022
SE16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
Former [2022/39]FI16.03.2022
HR16.03.2022
LT16.03.2022
LV16.03.2022
RS16.03.2022
SE16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
Former [2022/36]HR16.03.2022
LT16.03.2022
LV16.03.2022
RS16.03.2022
SE16.03.2022
BG16.06.2022
NO16.06.2022
GR17.06.2022
Former [2022/35]HR16.03.2022
LT16.03.2022
RS16.03.2022
SE16.03.2022
BG16.06.2022
NO16.06.2022
Former [2022/33]LT16.03.2022
NO16.06.2022
Cited inInternational search[A] WO2015108719  (WISCONSIN MED COLLEGE INC et al.) [A] 1-33 * paragraph [0097] - paragraph [0111] *
 [XA] US2015225483  (LO KIN-MING et al.) [X] 32,33 * the whole document *[A] 1-31
 [I] US2003194704  (PENN SHARRON GAYNOR et al.) [I] 11-16 * sequences 30631, 31535, 31353 * * claim 45 * * paragraph [0341] - paragraph [0343] * * paragraph [0346] - paragraph [0578] *
 [I] WO2004041170  (GENENTECH INC et al.) [I] 11-16 * claim 7; sequence 1608 *
 [I] US8168586  (FANG DONG et al.) [I] 11-16 * sequence 233 *
 [I] WO0190304  (HUMAN GENOME SCIENCES INC et al.) [I] 11-16 * claim 11; sequence 2080 *
 [IP] WO2017013188  (GENAGON THERAPEUTICS AB et al.) [IP] 1-33 * the whole document;; sequence 315 * * page 48 - page 53 *
 [E] WO2018050852  (GENAGON THERAPEUTICS AB et al.) [E] 1-33 * the whole document *
 [A]   ZHENHUA NI ET AL: "CLPTM1L Is Overexpressed in Lung Cancer and Associated with Apoptosis", PLOS ONE, vol. 7, no. 12, 26 December 2012 (2012-12-26), pages e52598, XP055175473, DOI: 10.1371/journal.pone.0052598 [A] 1-33 * abstract *

DOI:   http://dx.doi.org/10.1371/journal.pone.0052598
 [A]   NEUZILLET CINDY ET AL: "Targeting the TGF[beta] pathway for cancer the", PHARMACOLOGY AND THERAPEUTICS, vol. 147, 2015 - 2015, pages 22 - 31, XP029196208, ISSN: 0163-7258, DOI: 10.1016/J.PHARMTHERA.2014.11.001 [A] 1-33 * page 22 *

DOI:   http://dx.doi.org/10.1016/j.pharmthera.2014.11.001
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.